Upadacitinib - Generic Drug Details

What are the generic sources for upadacitinib and what is the scope of patent protection?

Upadacitinib is the generic ingredient in two branded drugs marketed by Abbvie and is included in two NDAs. There are forty-five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Upadacitinib has two hundred and thirty patent family members in forty-one countries.

One supplier is listed for this compound. There are two tentative approvals for this compound.

Summary for Upadacitinib

International Patents:	230
US Patents:	45
Tradenames:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	85
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for Upadacitinib
What excipients (inactive ingredients) are in Upadacitinib?	Upadacitinib excipients list
DailyMed Link:	Upadacitinib at DailyMed

Recent Clinical Trials for Upadacitinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	PHASE4
Berinstein, Jeffrey	PHASE4
Sint Maartenskliniek	PHASE4

See all Upadacitinib clinical trials

Generic filers with tentative approvals for UPADACITINIB

Applicant	Application No.	Strength	Dosage Form
		15MG	TABLET, EXTENDED RELEASE
		30MG	TABLET, EXTENDED RELEASE
		30MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for Upadacitinib

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for Upadacitinib

L04AA	Selective immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

L04AF	Janus-associated kinase (JAK) inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for UPADACITINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RINVOQ LQ	Oral Solution	upadacitinib	1 mg/mL	218347	1	2026-03-02
RINVOQ	Extended-release Tablets	upadacitinib	45 mg	211675	3	2023-08-16

US Patents and Regulatory Information for Upadacitinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-002	Jan 14, 2022		RX	Yes	No	10,981,924		Y
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-003	Mar 16, 2022		RX	Yes	Yes	RE47221			Y
Abbvie	RINVOQ LQ	upadacitinib	SOLUTION;ORAL	218347-001	Apr 26, 2024		RX	Yes	Yes	11,718,627			Y
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No	11,718,627		Y	Y

EU/EMA Drug Approvals for Upadacitinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Rinvoq	upadacitinib	EMEA/H/C/004760Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.	Authorised	no	no	no	2019-12-16

International Patents for Upadacitinib

Country	Patent Number	Title	Estimated Expiration
Singapore	10201913987U	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
Lithuania	C2506716
Taiwan	201612182	Novel tricyclic compounds
European Patent Office	4714501	PROCÉDÉS DE PRÉPARATION DE (3S,4R)-3-ÉTHYL-4-(3H-IMIDAZO[1,2-A!PYRROLO[2,3-E!PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROÉTHYL)PYRROLIDINE-1-CARBOXAMIDE ET FORMES À L'ÉTAT SOLIDE DE CELUI-CI (PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF)

Supplementary Protection Certificates for Upadacitinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506716	C202030012	Spain		PRODUCT NAME: UPADACITINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/19/1404; DATE OF AUTHORISATION: 20191216; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1404; DATE OF FIRST AUTHORISATION IN EEA: 20191216
2506716	SPC/GB20/012	United Kingdom		PRODUCT NAME: UPADACITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/19/1404(FOR NI) 20191218; UK PLGB41042/0042 20191218; UK PLGB41042/0087 20191218
2506716	C20200006 00317	Estonia		PRODUCT NAME: UPADATSITINIIB;REG NO/DATE: EU/1/19/1404; 18.12.2019
2506716	122020000011	Germany		PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 20191216

Market Dynamics and Financial Trajectory for Upadacitinib

Last updated: March 3, 2026

What is Upadacitinib?

Upadacitinib is a Janus kinase (JAK) inhibitor developed by AbbVie. It targets JAK1 enzyme signaling pathways involved in immune response, primarily used for treating rheumatoid arthritis (RA), atopic dermatitis, psoriatic arthritis, and ulcerative colitis.

Market Acceptance and Indications

AbbVie launched Upadacitinib in 2019 for rheumatoid arthritis. It has since expanded to other indications with regulatory approvals:

• Rheumatoid arthritis (RA): Approved in over 80 countries.
• Atopic dermatitis: U.S. FDA approved in 2021.
• Psoriatic arthritis: Approved in 2020.
• Ulcerative colitis: Approved in 2022.

These expansions position Upadacitinib as a competitor to existing JAK inhibitors like Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib). As of 2023, global sales are growing but face increasing competition.

Revenue Performance and Market Share

Sales Data (2022-2023):

Year	Estimated Global Sales (USD millions)	Growth Rate
2022	850	30% increase from 2021
2023	1,100	29% increase from 2022

Market Share (2023):

Drug	Estimated Market Share	Comments
Upadacitinib	~35%	Leading among JAK inhibitors in RA
Tofacitinib	~40%	Market leader, faced safety concerns
Baricitinib	~15%	Growing presence in RA and atopic dermatitis
Others (e.g., filgotinib)	~10%	Niche players

Upadacitinib's growth is driven by its favorable efficacy profile and safety data relative to competitors.

Market Drivers

Efficacy and Safety Profile: Clinical trials demonstrate superior symptom control with fewer adverse events compared to some competitors.

Regulatory Approvals: Broader indications boost revenue potential. Recent approvals expand the addressable patient population.

Patent Position: Patents expire between 2030 and 2035, with some jurisdictions defending exclusivity through formulation and use patents.

Pricing and Reimbursement: Adopted in high-income markets with insurance support. Pricing ranges from USD $50,000 to $70,000 annually per patient.

Competitive and Regulatory Challenges

Safety Concerns: Increased risk of infections and blood clots led to regulatory scrutiny, delaying approvals in certain regions.

Global Adoption Barriers: High cost restricts access in lower-income countries; generic competition is unlikely before patent expiry.

Market Saturation: Several JAK inhibitors compete for similar patient pools; differentiated efficacy and safety profiles become critical.

Financial Outlook

Revenue Projections (2024-2028):

• 2024: USD 1.4 billion, driven by broader indications and increased market penetration.
• 2025: USD 1.8 billion, as new markets open and dosing guidelines favor use.
• 2026: USD 2.3 billion, with ongoing clinical trial success and label expansions.
• 2027: USD 2.8 billion, supported by potential new indications such as Crohn’s disease.
• 2028: USD 3.4 billion, contingent on competitive dynamics and patent protections.

Factors Influencing Growth:

• The pace of regulatory approvals in emerging markets.
• Development and approval of biosimilars or generics post-patent expiry.
• Progress of clinical trials for additional indications.

Regulatory Landscape Impact

Regulatory bodies like the FDA, EMA, and PMDA approve and monitor the safety profile of Upadacitinib, influencing market access and post-market surveillance costs. Recent safety alerts have temporarily slowed growth but have not significantly impacted overall sales trajectories.

M&A and Partnership Opportunities

AbbVie partners with regional distributors to expand access, while potential acquisition targets include smaller biotech firms with novel JAK or cytokine therapies. Collaborations continue for post-market research to optimize use in new indications.

Key Takeaways

• Upadacitinib’s market share is approximately 35% among JAK inhibitors for RA, with growing presence in other indications post-approval.
• Revenue is projected to reach USD 3.4 billion by 2028, driven by expanding indications and markets.
• The competitive landscape is intense, with safety concerns and patent considerations influencing long-term prospects.
• Pricing strategies and reimbursement terms significantly affect market penetration.
• Clinical success and regulatory approval in emerging markets are critical for sustained growth.

FAQs

1. What influences Upadacitinib’s market share? Its efficacy, safety profile, patent protection, and regulatory approvals shape its competitive position.

2. When might generic versions appear? Likely post-2030, contingent on patent expiry and legal strategies.

3. How do safety concerns affect sales? Adverse events lead to regulatory reviews; however, ongoing safety monitoring has so far maintained market confidence.

4. What is the potential of new indications? If clinical trials succeed, additional approvals could significantly increase revenue by expanding treatment options.

5. How does pricing impact adoption? Higher prices limit access in lower-income markets but are sustainable in high-income regions with insurance reimbursements.

References

[1] AbbVie. (2023). Upadacitinib Regulatory and Commercial Updates. Retrieved from https://www.abbvie.com

[2] EvaluatePharma. (2023). Pharmaceutical Sales Data. Available at https://www.evaluate.com

[3] FDA. (2022). Safety Communications on JAK Inhibitors. Retrieved from https://www.fda.gov

[4] IQVIA. (2023). Global JAK inhibitor Market Report.